Featured Research

from universities, journals, and other organizations

New Treatment Allow Patients To Return To Pre-injury Activity

Date:
May 4, 2006
Source:
American Roentgen Ray Society
Summary:
Ultrasound-guided, intra-tendonous injection of a dextrose solution is a very effective treatment for certain chronic tendonoses in the leg, reported radiologists.

Ultrasound-guided, intra-tendonous injection of a dextrose solution is a very effective treatment for certain chronic tendonoses in the leg, reported radiologists from the department of radiology at St. Paul's Hospital and the Department of Family Practice at the University of British Columbia both in Vancouver, BC.

According to the report, 43 of 53 tendons (32 of 36 Achilles tendons and 11 of 17 infrapatella tendons) were successfully treated by ultrasound guided injections of hyperosmolar dextrose. These patients suffered from pain at rest and during normal daily activity as well as during and/or after physical/sporting activity.

"I'd observed that the abnormal tendons were thickened and often demonstrated clefts or tears within their substance, and it was these findings that needed treatment, said A.D. Wong, MD, lead researcher of this study. "Hyperosmolar dextrose, among other substances has been used to sclerose tendon and ligament insertions for many years but these injections were not under sonographic guidance or into the body of the tendons."

"I have been performing this procedure for just under three years and a high percentage of the chronically disabled patients have been able to return to their normal pre-injury activities," said Dr. Wong. "The patients range from marathon runners and athletes in many other sports to ordinary citizens."

"I have since expanded the treatment successfully to include tendonopathy of the elbow and for plantar fascitis and several other sites. It may have value in treating some shoulder tendonpathies but further studies are needed," said Dr. Wong.

The full results of this study will be presented on Wednesday, May 3, 2006 during the American Roentgen Ray Society's annual meeting in Vancouver, BC.


Story Source:

The above story is based on materials provided by American Roentgen Ray Society. Note: Materials may be edited for content and length.


Cite This Page:

American Roentgen Ray Society. "New Treatment Allow Patients To Return To Pre-injury Activity." ScienceDaily. ScienceDaily, 4 May 2006. <www.sciencedaily.com/releases/2006/05/060504075621.htm>.
American Roentgen Ray Society. (2006, May 4). New Treatment Allow Patients To Return To Pre-injury Activity. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2006/05/060504075621.htm
American Roentgen Ray Society. "New Treatment Allow Patients To Return To Pre-injury Activity." ScienceDaily. www.sciencedaily.com/releases/2006/05/060504075621.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins